Guard Therapeutics International AB logo

Guard Therapeutics International AB (GUARD)

Market Closed
10 Aug, 15:25
XSTO XSTO
XSTO XSTO Primary
kr
1. 25
-0.13
-9.6681%
kr
33.07M Market Cap
- P/E Ratio
- Div Yield
59,098 Volume
-12.7 Eps
kr 1.39
Previous Close
Add Transaction
Day Range
1.23 1.33
Year Range
0.88 27
Want to track GUARD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

GUARD closed today lower at kr1.25, a decrease of -9.6681% from yesterday's close, completing a monthly increase of 25.2% or kr0.25. Over the past 12 months, GUARD stock lost -15.4054%.
GUARD is not paying dividends to its shareholders.
The last earnings report, released on May 04, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.7009%, based on the last three reports.
Guard Therapeutics International AB has completed 2 stock splits, with the recent split occurring on Dec 15, 2023.
The company's stock is traded on one exchange.

GUARD Chart

No Data

People also search for

ONCOZ
OncoZenge AB
kr 5.75
-7.4074%
FRISQ
FRISQ Holding AB
kr 0.7
+6.383%
SDOS
ScandiDos AB
kr 0.92
+2.809%
GPXMED
GPX Medical AB
kr 2.13
-0.9302%
REDS
Redsense Medical AB
kr 4
+0.2506%

Guard Therapeutics International AB (GUARD) FAQ

What is the stock price today?

The current price is kr1.25.

On which exchange is it traded?

Guard Therapeutics International AB is listed on XSTO.

What is its stock symbol?

The ticker symbol is GUARD.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 33.07M.

Has Guard Therapeutics International AB ever had a stock split?

Guard Therapeutics International AB had 2 splits and the recent split was on Dec 15, 2023.

Guard Therapeutics International AB Profile

Biotechnology Industry
Healthcare Sector
Mr. Tobias Larsson Agervald CEO
XSTO Exchange
SE0009973357 ISIN
SE Country
12 Employees
- Last Dividend
15 Dec 2023 Last Split
- IPO Date

Overview

Guard Therapeutics International AB (publ) is a pioneering pharmaceutical company based in Stockholm, Sweden, focusing on the discovery, development, and commercialization of innovative therapies for the diagnosis and treatment of acute kidney injuries. Originating in 2008 under the name A1M Pharma AB (publ), the company underwent a significant rebranding to become Guard Therapeutics International AB (publ) in October 2019. With a dedicated mission to advance kidney health, Guard Therapeutics aims to transform the landscape of renal care through its groundbreaking research and pharmaceutical solutions.

Products and Services

  • ROSGard

Guard Therapeutics' flagship product, ROSGard, stands at the forefront of their innovative offerings. This biological drug candidate embodies the company's commitment to preventing kidney damage during acute incidents. ROSGard's therapeutic action is multi-faceted, designed to protect, clean, and repair cells and tissues that become exposed during acute kidney injuries. By targeting these vital processes, ROSGard promises to offer substantial benefits to patients suffering from such dire conditions, highlighting Guard Therapeutics' significant contribution to renal health and medical science.

Contact Information

Address: Dag Hammarskjölds Väg 54B, Uppsala, Sweden, 751 83
Phone: 46 86 70 65 51
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark